Cargando…
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) have emerged as one of the most promising immune checkpoint targets for cancer immunotherapy. Despite the inherent advantages of small-molecule inhibitors over antibodies, the discovery of small-molecule inhibitors has fallen behind...
Autores principales: | Sun, Chengliang, Cheng, Yao, Liu, Xiaojia, Wang, Gefei, Min, Wenjian, Wang, Xiao, Yuan, Kai, Hou, Yi, Li, Jiaxing, Zhang, Haolin, Dong, Haojie, Wang, Liping, Lou, Chenguang, Sun, Yanze, Yu, Xinmiao, Deng, Hongbin, Xiao, Yibei, Yang, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764071/ https://www.ncbi.nlm.nih.gov/pubmed/36561991 http://dx.doi.org/10.1016/j.apsb.2022.04.007 |
Ejemplares similares
-
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
por: Sun, Yanze, et al.
Publicado: (2023) -
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023) -
Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review
por: Zheng, Huilan, et al.
Publicado: (2023) -
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020) -
An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)